Abstract 169P
Background
In the phase III IMbrave150 trial, atezo + bev demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) vs sorafenib (sor) in patients (pts) with unresectable HCC. Here we report on the AESIs for both atezo and bev in IMbrave150.
Methods
Eligible pts (N = 501) had unresectable HCC and were randomised 2:1 to receive atezo 1200 mg IV q3w + bev 15 mg/kg IV q3w or sor 400 mg PO bid until unacceptable toxicity or loss of clinical benefit per investigator. Co-primary endpoints were OS and PFS by independent review facility–assessed RECIST 1.1. AESIs were defined by the sponsor and reported without judgement of causality. AESIs for atezo were based on the immune-mediated risks of atezo and other checkpoint inhibitors; AESIs for bev were based on known adverse drug reactions (ADRs) with bev. Analyses explored the incidence, nature and severity of AESIs as well as corticosteroid use.
Results
The safety-evaluable population included 329 pts in the atezo + bev arm and 156 pts in the sor arm. Median follow-up was 8.6 mo (data cutoff: 29 Aug 2019); median tx durations were 7.4 (atezo), 6.9 (bev) and 2.8 (sor) mo. AESIs for atezo occurred in 69% of pts receiving atezo + bev and also in 82% of pts receiving sor (Table). 12% of pts in the atezo + bev arm vs 3% of pts in the sor arm experienced AESIs requiring systemic corticosteroid tx within 30 days of AE onset. AESIs for bev occurred in 58% of pts receiving atezo + bev and 49% of pts receiving sor. The reported events were ADRs well known with bev, and their frequency and severity were consistent with the safety profile of bev and the underlying disease.
Conclusions
In IMbrave150, AESIs for atezo and bev were manageable. Further, the nature and severity of AESIs were consistent with the known safety profiles of the individual agents and the underlying disease Table: 169P
AESIs, n (%)a | Atezo + Bev n = 329 | Sor n = 156 | ||
All | G3-4 | All | G3-4 | |
For atezo | ||||
Pts with ≥ 1 | 226 (69) | 85 (26) | 128 (82) | 47 (30) |
Hepatic eventsb | 142 (43) | 70 (21) | 62 (40) | 26 (17) |
Inc AST | 64 (20) | 23 (7) | 26 (17) | 8 (5) |
Inc blood bilirubin | 43 (13) | 8 (2) | 22 (14) | 10 (6) |
Inc ALT | 46 (14) | 12 (4) | 14 (9) | 2 (1) |
Ascites | 23 (7) | 6 (2) | 9 (6) | 2 (1) |
Rash | 64 (20) | 2 (1) | 96 (62) | 21 (14) |
Hypothyroidism | 36 (11) | 0 | 4 (3) | 0 |
Infusion-related reactions | 36 (11) | 8 (2) | 0 | 0 |
For bev | ||||
Pts with ≥ 1 | 190 (58) | 76 (23) | 76 (49) | 29 (19) |
Hypertension | 102 (31) | 50 (15) | 40 (26) | 19 (12) |
Bleeding/haemorrhage | 83 (25) | 21 (6) | 27 (17) | 9 (6) |
Epistaxis | 34 (10) | 0 | 7 (5) | 1 (1) |
Upper GI bleedingc | 24 (7) | 15 (5) | 8 (5) | 8 (5) |
Proteinuria | 70 (21) | 10 (3) | 13 (8) | 1 (1) |
Inc, increased. a In ≥ 5% of pts. b ≥ 1 category possible. c Grouped MedDRA PT
.Clinical trial identification
NCT03434379.
Editorial acknowledgement
Medical writing assistance for this abstract was provided by Kia C. E. Walcott, PhD of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche, Ltd.
Funding
F. Hoffmann-La Roche, Ltd.
Disclosure
M. Kudo: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Eisai; Honoraria (self): Bayer; Honoraria (self), Honoraria (institution): MSD; Honoraria (self), Honoraria (institution): BMS; Honoraria (self): Lilly; Honoraria (institution), Research grant/Funding (institution): EA Pharma; Research grant/Funding (institution): Gilead Sciences; Research grant/Funding (institution): Taiho; Research grant/Funding (institution): Sumitomo Dainippon Pharma; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Otsuka; Research grant/Funding (institution): AbbVie; Advisory/Consultancy: Ono; Advisory/Consultancy: Roche. M. Ikeda: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Lilly; Honoraria (self): Taiho; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Chugai; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Research grant/Funding (institution): Yakult; Honoraria (self): Teijin; Honoraria (self), Advisory/Consultancy: Servier; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Eisai; Honoraria (self), Research grant/Funding (institution): Bayer; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Ono; Research grant/Funding (institution): Bristol-Myers; Research grant/Funding (institution): MSD; Research grant/Funding (institution): J-Pharma; Research grant/Funding (institution): Aslan; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Merck Serono; Research grant/Funding (institution): Astellas. A.X. Zhu: Advisory/Consultancy: Lilly; Advisory/Consultancy: Bayer; Advisory/Consultancy: Roche; Advisory/Consultancy: Merck; Advisory/Consultancy: Sanofi; Advisory/Consultancy: Exelixis; Advisory/Consultancy: Eisai. H.Y. Lim: Advisory/Consultancy: Bayer; Advisory/Consultancy: Eisai; Advisory/Consultancy: BMS; Advisory/Consultancy: Ono; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Roche. V. Breder: Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: Bayer; Advisory/Consultancy, Travel/Accommodation/Expenses: Eisai; Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy: Ipsen. P. Merle: Advisory/Consultancy, Ad Board: Bayer; Advisory/Consultancy, Ad Board: Eisai; Advisory/Consultancy, Ad Board: Exelixis; Advisory/Consultancy, Ad Board: Ipsen; Advisory/Consultancy, Ad Board: Lilly; Advisory/Consultancy, Ad Board: Roche; Advisory/Consultancy, Ad Board: AstraZeneca; Advisory/Consultancy, Ad Board: BMS; Advisory/Consultancy, Ad Board: MSD; Advisory/Consultancy, Ad Board: Merck; Advisory/Consultancy, Ad Board: Onxeo. A. Kaseb: Honoraria (self), Research grant/Funding (institution), Research Support: Genentech/Roche; Research grant/Funding (institution), Research Support: BMS; Research grant/Funding (institution), Research Support: Exelixis; Research grant/Funding (institution), Research Support: Bayer; Research grant/Funding (institution), Research Support: AdaptImmune; Research grant/Funding (institution), Research Support: Immatics; Research grant/Funding (institution), Research Support: Merck; Research grant/Funding (institution), Research Support: Eisai. D. Li: Advisory/Consultancy: Genentech. N. Ma: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech/Roche. M. Villalobos: Full/Part-time employment: Genentech/Roche. S. Stanzel: Shareholder/Stockholder/Stock options, Full/Part-time employment: Roche. V.E. Gaillard: Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options, Full/Part-time employment: Roche. D-Z. Xu: Full/Part-time employment: Roche. S. Hernandez: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech/Roche. A-L. Cheng: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self): Yakuhin; Honoraria (self), Advisory/Consultancy: Eisai; Honoraria (self), Advisory/Consultancy: Genentech/Roche; Honoraria (self): Lilly; Advisory/Consultancy: Bayer Schering Pharma; Advisory/Consultancy: BeiGene, Ltd; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: CSR Pharma Group; Advisory/Consultancy: IQVIA; Advisory/Consultancy: MSD; Advisory/Consultancy: Novartis; Advisory/Consultancy: Ono Pharmaceutical. R.S. Finn: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy, Research grant/Funding (institution): Eisai; Advisory/Consultancy: Exelixis; Advisory/Consultancy, Research grant/Funding (institution): Genentech/Roche; Advisory/Consultancy, Research grant/Funding (institution): Lilly; Advisory/Consultancy, Research grant/Funding (institution): Merck; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Pfizer. P.R. Galle: Honoraria (self): Bayer; Speaker Bureau/Expert testimony: BMS; Honoraria (self): AstraZeneca; Honoraria (self): Lilly; Honoraria (self): Sirtex; Honoraria (self): MSD; Honoraria (self): Ipsen; Honoraria (self): Roche; Advisory/Consultancy: SillaJen; Advisory/Consultancy: Eisai. M. Ducreux: Full/Part-time employment: Sandoz (I); Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Honoraria (self), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Bayer; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Celgene; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Serono; Honoraria (self): MSD Oncology; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self): Roche/Genentech; Honoraria (self), Advisory/Consultancy: Servier; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Speaker Bureau/Expert testimony: Merck KGaA; Research grant/Funding (institution): Keocyt. All other authors have declared no conflicts of interest.
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session